143 related articles for article (PubMed ID: 11779297)
21. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow involvement in T-cell-rich B-cell lymphoma.
Skinnider BF; Connors JM; Gascoyne RD
Am J Clin Pathol; 1997 Nov; 108(5):570-8. PubMed ID: 9353097
[TBL] [Abstract][Full Text] [Related]
23. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
24. [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
Kataoka T; Ishida Y; Kurokawa R; Takeshita S; Ohta K; Nishimura Y; Yokoyama M
Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):899-904. PubMed ID: 14727553
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
[TBL] [Abstract][Full Text] [Related]
26. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.
Foran JM; Norton AJ; Micallef IN; Taussig DC; Amess JA; Rohatiner AZ; Lister TA
Br J Haematol; 2001 Sep; 114(4):881-3. PubMed ID: 11564080
[TBL] [Abstract][Full Text] [Related]
27. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
[TBL] [Abstract][Full Text] [Related]
28. Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases.
Papadaki T; Stamatopoulos K; Stavroyianni N; Paterakis G; Phisphis M; Stefanoudaki-Sofianatou K
Leuk Res; 2002 Jun; 26(6):597-600. PubMed ID: 12007508
[TBL] [Abstract][Full Text] [Related]
29. Clinical status and optimal use of rituximab for B-cell lymphomas.
McLaughlin P; White CA; Grillo-López AJ; Maloney DG
Oncology (Williston Park); 1998 Dec; 12(12):1763-9; discussion 1769-70, 1775-7,. PubMed ID: 9874849
[TBL] [Abstract][Full Text] [Related]
30. Hodgkin's and non-Hodgkin's lymphomas.
Rademaker J
Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
[TBL] [Abstract][Full Text] [Related]
31. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
[TBL] [Abstract][Full Text] [Related]
32. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
[TBL] [Abstract][Full Text] [Related]
33. Differential diagnosis of L26-positive, CD15-negative Hodgkin's disease and large B-cell lymphoma with a high content of reactive T-cells: a morphologic and immunohistochemical study.
Nguyen DT; Diamond LW; Hansmann ML; Fischer R
Hematopathol Mol Hematol; 1996; 10(3):135-50. PubMed ID: 8878732
[TBL] [Abstract][Full Text] [Related]
34. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
35. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
36. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
37. T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma.
Aki H; Tuzuner N; Ongoren S; Baslar Z; Soysal T; Ferhanoglu B; Sahinler I; Aydin Y; Ulku B; Aktuglu G
Leuk Res; 2004 Mar; 28(3):229-36. PubMed ID: 14687617
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
Ansell SM; Witzig TE; Kurtin PJ; Sloan JA; Jelinek DF; Howell KG; Markovic SN; Habermann TM; Klee GG; Atherton PJ; Erlichman C
Blood; 2002 Jan; 99(1):67-74. PubMed ID: 11756154
[TBL] [Abstract][Full Text] [Related]
39. T-cell rich b-cell non-hodgkin's lymphoma: a progressed form of follicle centre cell lymphoma and lymphocyte predominance hodgkin's disease.
De Jong D; Van Gorp J; Sie-Go D; Van Heerde P
Histopathology; 1996 Jan; 28(1):15-24. PubMed ID: 8838116
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
